Author response for "Dual <scp>GIP</scp> and <scp>GLP</scp> ‐1 Receptor Agonist, Tirzepatide, Improves Lipoprotein Biomarkers Associated with Insulin Resistance and Cardiovascular Risk in Patients with Type 2 Diabetes"
crossref（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要